JP7812051B2 - 神経変性および代謝障害の処置のための化合物 - Google Patents

神経変性および代謝障害の処置のための化合物

Info

Publication number
JP7812051B2
JP7812051B2 JP2021568115A JP2021568115A JP7812051B2 JP 7812051 B2 JP7812051 B2 JP 7812051B2 JP 2021568115 A JP2021568115 A JP 2021568115A JP 2021568115 A JP2021568115 A JP 2021568115A JP 7812051 B2 JP7812051 B2 JP 7812051B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
nad
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532379A5 (enExample
JP2022532379A (ja
Inventor
ラスメザス，コリーヌ
チョウ，ミンハイ
バニスター，トーマス，ディー．
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2022532379A publication Critical patent/JP2022532379A/ja
Publication of JP2022532379A5 publication Critical patent/JP2022532379A5/ja
Priority to JP2025280205A priority Critical patent/JP2026048976A/ja
Application granted granted Critical
Publication of JP7812051B2 publication Critical patent/JP7812051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/10—Quaternary compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021568115A 2019-05-14 2020-05-14 神経変性および代謝障害の処置のための化合物 Active JP7812051B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025280205A JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847600P 2019-05-14 2019-05-14
US62/847,600 2019-05-14
PCT/US2020/032903 WO2020232255A1 (en) 2019-05-14 2020-05-14 Compounds for the treatment of neurodegenerative and metabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025280205A Division JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Publications (3)

Publication Number Publication Date
JP2022532379A JP2022532379A (ja) 2022-07-14
JP2022532379A5 JP2022532379A5 (enExample) 2023-07-12
JP7812051B2 true JP7812051B2 (ja) 2026-02-09

Family

ID=70978576

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568115A Active JP7812051B2 (ja) 2019-05-14 2020-05-14 神経変性および代謝障害の処置のための化合物
JP2025280205A Pending JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025280205A Pending JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Country Status (9)

Country Link
US (1) US12590094B2 (enExample)
EP (1) EP3968981A1 (enExample)
JP (2) JP7812051B2 (enExample)
CN (1) CN114173774A (enExample)
AU (2) AU2020274186A1 (enExample)
BR (1) BR112021022734A2 (enExample)
CA (2) CA3297266A1 (enExample)
IL (2) IL288001B2 (enExample)
WO (1) WO2020232255A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021377893A1 (en) * 2020-11-12 2023-06-22 Scripps Research Institute, The Nicotinamide dinucleotide (nad) detection and quantification
JP2024501625A (ja) * 2020-12-11 2024-01-15 ザ スクリプス リサーチ インスティテュート 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用
IL303924A (en) * 2020-12-18 2023-08-01 Scripps Research Inst Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
CN117355300A (zh) * 2021-01-15 2024-01-05 佛罗里达大学研究基金会公司 化合物及其用于治疗神经退行性、退行性以及代谢疾病的用途
WO2022165173A1 (en) * 2021-01-28 2022-08-04 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
JP2024516827A (ja) 2021-04-30 2024-04-17 マインド メディシン， インコーポレイテッド Ｌｓｄ塩結晶形態
WO2022235531A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Movement disorders
KR20240007258A (ko) * 2021-05-13 2024-01-16 유니버시티 오브 싸우스 캐롤라이나 리실 옥시다제의 억제제로서 비티아졸 유도체
AU2022331315B2 (en) 2021-08-19 2025-10-16 Definium Therapeutics US, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
CN116036279A (zh) * 2022-07-27 2023-05-02 上海交通大学医学院附属新华医院 Echs1抑制剂的用途
CN121002020A (zh) * 2022-12-13 2025-11-21 韦夫布雷克治疗有限责任公司 治疗与蛋白质错误折叠相关的病症的化合物、组合物和方法
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
EP4643856A1 (en) * 2024-05-03 2025-11-05 Centre National de la Recherche Scientifique Carbazole derivatives used as neuroprotectants and in the treatment of disorders with reduced nad metabolism

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508800A (ja) 1997-02-13 2001-07-03 ノバルティス アクチエンゲゼルシャフト 血管形成阻害活性を有するフタラジン
US20040116434A1 (en) 2002-11-07 2004-06-17 Campochiaro Peter A. Ocular therapy
WO2006108107A1 (en) 2005-04-06 2006-10-12 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
WO2016085990A1 (en) 2014-11-24 2016-06-02 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity
WO2017015660A1 (en) 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017160864A1 (en) 2016-03-14 2017-09-21 Board Of Regents, The University Of Texas System Hydralazine and active derivatives thereof for neuronal cell survival and regeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6903101B1 (en) * 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
JP4852540B2 (ja) * 2004-06-30 2012-01-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのフタラジン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508800A (ja) 1997-02-13 2001-07-03 ノバルティス アクチエンゲゼルシャフト 血管形成阻害活性を有するフタラジン
US20040116434A1 (en) 2002-11-07 2004-06-17 Campochiaro Peter A. Ocular therapy
WO2006108107A1 (en) 2005-04-06 2006-10-12 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
WO2016085990A1 (en) 2014-11-24 2016-06-02 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity
WO2017015660A1 (en) 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017160864A1 (en) 2016-03-14 2017-09-21 Board Of Regents, The University Of Texas System Hydralazine and active derivatives thereof for neuronal cell survival and regeneration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A． ANAND et al.，"Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients"，European Journal of Neurology，2011年10月07日，Vol. 19, No. 5，p.788-792，DOI: 10.1111/j.1468-1331.2011.03548.x（特に、要約を参照）
Alice BROCKINGTON et al.，"Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis"，BMC Medical Genetics，2007年04月24日，Vol. 8, No. 1，DOI: 10.1186/1471-2350-8-23（特に、要約を参照）
and immunology，Correlation of Serum Levels of IL-33, and Circulatory Frequency of VEGFR2-expressing Cells with Multiple Sclerosis Severity, Correlation of Serum Levels of IL-33，Iranian journal of allergy，AKBARI,H.，2017年，Vol.16, No.4，p.329-337
Anna LUNDIN et al.，"Two novel fusion inhibitors of human respiratory syncytial virus"，Antiviral Research，2010年12月，Vol. 88, No. 3，p.317-324
C．E. WHITTLES et al.，"ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor‐Receptor‐2 Tyrosine Kinase Activity"，Microcirculation，2002年12月，Vol. 9, No. 6，p.513-522，DOI: 10.1038/sj.mn.7800164
Sun-Jung CHO et al.，"VEGFR2 alteration in Alzheimer’s disease"，Scientific Reports，2017年12月18日，Vol. 7, No. 1，DOI: 10.1038/s41598-017-18042-1

Also Published As

Publication number Publication date
IL288001B2 (en) 2026-02-01
CA3140044A1 (en) 2020-11-19
WO2020232255A1 (en) 2020-11-19
JP2026048976A (ja) 2026-03-17
CN114173774A (zh) 2022-03-11
JP2022532379A (ja) 2022-07-14
CA3297266A1 (en) 2026-03-02
AU2026201203A1 (en) 2026-03-05
IL288001B1 (en) 2025-10-01
AU2020274186A1 (en) 2021-12-09
BR112021022734A2 (pt) 2022-03-08
IL288001A (en) 2022-01-01
US12590094B2 (en) 2026-03-31
US20230041523A1 (en) 2023-02-09
EP3968981A1 (en) 2022-03-23
IL323398A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
JP2026048976A (ja) 神経変性および代謝障害の処置のための化合物
AU2018202438B2 (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
AU2005265270B2 (en) Heterocyclic derivatives for modulation of calcium channels
CN102143744B (zh) 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途
EP3570940B1 (en) Pridopidine for use in the treatment of fragile x syndrome
WO2016004254A1 (en) Combined modulation of ire1
JP2015532287A (ja) Ｉｒｅ１の調節
Noh et al. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer’s disease
EP3394083B9 (en) N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis
KR20200019228A (ko) 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
WO2022086581A1 (en) Methods of treating 4-repeat tauopathies
WO2011057110A1 (en) Gpr109a agonists for the treatment of cerebral ischemia
HK40061395A (en) Compounds for the treatment of neurodegenerative and metabolic disorders
AU2022212106A1 (en) Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
WO2019222393A1 (en) Neuroprotective compositions and methods of using the same
AU2021401429A1 (en) Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
Legatrin et al. QUININE SULFATE
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
HK40073574B (zh) 以稠合嘧啶化合物为有效成分的治疗剂
Bergantin et al. Advances for The pharmacotherapy of Alzheimers Disease: The Ca2+/cAMP Signaling Interaction
HK40009984A (en) Erbb inhibitors and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251222

R150 Certificate of patent or registration of utility model

Ref document number: 7812051

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150